Rapid policy statement: Ruxolitinib for acute graft versus host disease

The most common treatment option for corticosteroid-refractory graft versus host disease is extracorporeal photopheresis. Ruxolitinib provides an alternative option which can be taken at home, and this document sets out recommendations for its use in the context of Covid-19.

SPS commentary:

There is emerging evidence of efficacy of ruxolitinib in acute graft versus host disease (GvHD) and it has been approved for this indication in the US. This policy statement was based on review of three papers (detailed in Appendix 1), including a Phase III trial (REACH2). 

NHS England